The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Combination Therapy in Alzheimer???s Disease: A Review of Current Evidence
Abstract
Treating dementia has become a major challenge in clinical practice. Presently, acetylcholinesterase inhibitors are the first-line drugs in the treatment of Alzheimer's disease (AD). These options are now complemented by memantine, which is approved for the treatment of moderate-to-severe AD. Altogether, a minimum of six agent classes already exist, all of which are approved for clinical use and are either already being tested or ready for phase III clinical trials for the treatment of AD. These include cholinesterase inhibitors, blockers of the NMDA receptor, antioxidants or blockers of oxidative deamination (including Gingko biloba), anti-inflammatory agents, neurotrophic factors (including hormone replacement therapy and drugs acting on insulin signal transduction) and antiamyloid agents (including cholesterol-lowering therapy). These approaches hold promise for disease modification and have a potential to be used as combination therapy for cognitive enhancement. Presently, only nine clinical studies have been published that have investigated the effects of a combination regimen on cognitive performance or AD. Among those, one study was conducted in elderly cognitively intact persons; the others involved patients with AD. Only five of the treatment studies followed a randomised, controlled design. Not all studies favoured the superior efficacy of combination therapy over monotherapy. Some studies, however, showed some evidence for synergistic combination effects of symptomatic therapy, including delay or prevention of disease progression in AD patients. In addition, six studies investigated the effects of AChE inhibitor in combination with antipsychotic or antidepressant therapy on behavioural aspects of AD symptomatology. In four of those studies there were indications that combination therapy had greater efficacy over monotherapy. The treatment of AD patients requires optimised options for all stages of illness based on the available drugs. There is a great need for further well designed studies on combination therapy in AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It should be noted that AChE inhibitors could be part of any combination therapy against AD [100].”
From Chemical Constituents and Pharmacological Activities of Garlic (Allium sativum L.): A Review (2020) · cites this paper as [100]
In the citing paper
“Antioxidants such as tocopherol, selegiline, and ascorbic acid (vitamin C) were examined as a possible preventive therapy for AD, and they show delayed functional deterioration in AD patients [100].”
From Chemical Constituents and Pharmacological Activities of Garlic (Allium sativum L.): A Review (2020) · cites this paper as [100]
Citations
Cites
1 retracted
Davis, R. E., Miller, S., Herrnstadt, C., Ghosh, S. S., Fahy, E., Shinobu, L. A., Galasko, D., Thal, L. J., Beal, M. F., Howell, N., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4526 · Cited by 341
RetractedDiagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,137
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01683-7 · Cited by 1,909
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
Ownby, R. L., Crocco, E., Acevedo, A., John, V., & Loewenstein, D. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.5.530 · Cited by 1,493
Wolozin, B. L. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,408
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L., Hempelman, S. R., Berry, D. A., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 991
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Effect of Estrogen Plus Progestin on Global Cognitive Function in Postmenopausal Women
Rapp, S. R., Espeland, M. A., Shumaker, S. A., Henderson, V. W., Brunner, R. L., Manson, J. E., Gass, M. L. S., Stefanick, M. L., Lane, D. S., Hays-Grudo, J., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2663 · Cited by 939
Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lütjohann, D., Keller, P., Runz, H., Kühl, S., Bertsch, T., von Bergmann, K., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081620098 · Cited by 860
Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10
Kojro, E., Gimpl, G., Lammich, S., März, W., & Fahrenholz, F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081612998 · Cited by 804
Oxidative Alterations in Alzheimer's Disease
Markesbery, W. R., & Carney, J. M. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00215.x · Cited by 789
Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1445 · Cited by 623
Ginkgo biloba for cognitive impairment and dementia
Birks, J., & Evans, J. G. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003120.pub3 · Cited by 615
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
Feldman, H., Gauthier, S. G., Hecker, J., Vellas, B. J., Subbiah, P., Whalen, E., & the Donepezil MSAD Study Investigators Group* (2001) · Neurology · doi:10.1212/wnl.57.4.613 · Cited by 600
100 Years and Counting: Prospects for Defeating Alzheimer's Disease
Roberson, E. D., & Mucke, L. (2006) · Science · doi:10.1126/science.1132813 · Cited by 556
Hansen, R. A., Webb, A. P., Moore, C. G., Gartlehner, G., Jonas, D. E., & Morgan, L. C. (2020) · PubMed Central · doi:10.17615/ae8c-2p76 · Cited by 523
Luine, V. N. (1985) · Experimental Neurology · doi:10.1016/0014-4886(85)90108-6 · Cited by 523
To: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
(2001) · Neurology · doi:10.1212/wnl.57.11.2153-a · Cited by 491
Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., & Landreth, G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07504.2003 · Cited by 469
Toran‐Allerand, C. D., Miranda, R. C., Bentham, W. D. L., Sohrabji, F., Brown, T. J., Hochberg, R. B., & MacLusky, N. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4668 · Cited by 428
Simons, M., Schwärzler, F., Lütjohann, D., von Bergmann, K., Beyreuther, K. T., DICHGANS, J., Wormstall, H., Hartmann, T., & Schulz, J. B. (2002) · Annals of Neurology · doi:10.1002/ana.10292 · Cited by 413
Danysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404
The Role of Insulin Resistance in the Pathogenesis of Alzheimer??s Disease
Watson, G. S., & Craft, S. (2003) · CNS Drugs · doi:10.2165/00023210-200317010-00003 · Cited by 400
Winblad, B. G., Kilander, L., Eriksson, S., Minthon, L., Båtsman, S., Wetterholm, A.-L., Jansson-Blixt, C., & Haglund, A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68350-5 · Cited by 400
Kanowski, S., Herrmann, W., Stephan, K., Wierich, W., & Hörr, R. (1996) · Pharmacopsychiatry · doi:10.1055/s-2007-979544 · Cited by 369
Dyrks, T., Dyrks, E., Hartmann, T., Masters, C. L., & Beyreuther, K. T. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)37174-1 · Cited by 343
Vitamin E and Vitamin C Supplement Use and Risk of Incident Alzheimer Disease
Morris, M. C., Beckett, L. A., Scherr, P. A., Hebert, L. E., Bennett, D. A., Field, T. S., & Evans, D. A. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199809000-00001 · Cited by 332
The Increasing Use of Polypharmacotherapy for Refractory Mood Disorders
Frye, M. A., Ketter, T. A., Leverich, G. S., Huggins, T., Lantz, C., Denicoff, K. D., & Post, R. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0104 · Cited by 315
Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial
Peskind, E. R., Potkin, S. G., Pomara, N., Ott, B. R., Graham, S. M., Olin, J. T., & McDonald, S. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000224350.82719.83 · Cited by 308
Misonou, H., Morishima-Kawashima, M., & Ihara, Y. (2000) · Biochemistry · doi:10.1021/bi000169p · Cited by 304
Psychiatric Symptoms Vary With the Severity of Dementia in Probable Alzheimer's Disease
Lopez, O. L., Becker, J. T., Sweet, R. A., Klunk, W., Kaufer, D. I., Saxton, J., Habeych, M., & DeKosky, S. T. (2003) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.15.3.346 · Cited by 286
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., et al. (2002) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(01)00776-8 · Cited by 285
Thiazolidinediones in Type 2 Diabetes Mellitus
Diamant, M., & Heine, R. J. (2003) · Drugs · doi:10.2165/00003495-200363130-00004 · Cited by 281
Krüger, R., Vieira-Saecker, A. M. M., Kuhn, W., Berg, D., M�ller, T., K�hnl, N., Fuchs, G., Storch, A., Hungs, M., Woitalla, D., et al. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199905)45:5 · Cited by 281
Porsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884576 · Cited by 272
Waddington, J. L., Youssef, H. A., & Kinsella, A. (1998) · The British Journal of Psychiatry · doi:10.1192/bjp.173.4.325 · Cited by 268
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266
Freudenreich, O., & GOFF, D. C. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.01331.x · Cited by 260
Donepezil preserves cognition and global function in patients with severe Alzheimer disease
Black, S. E., Doody, R., Li, H., McRae, T. D., Jambor, K. M., Xu, Y., Sun, Y., Perdomo, C. A., & Richardson, S. (2007) · Neurology · doi:10.1212/01.wnl.0000266627.96040.5a · Cited by 256
Efficacy of Donepezil in Early-Stage Alzheimer Disease
Seltzer, B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1852 · Cited by 256
The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba
Watanabe, C. M. H., Wolffram, S., Ader, P., Rimbach, G. H., Packer, L., Maguire, J. J., Schultz, P. G., & Gohil, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111126298 · Cited by 234
Long-term course and effectiveness of combination therapy in Alzheimer disease
Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230
Memantine Improves Cognition and Reduces Alzheimer’s-Like Neuropathology in Transgenic Mice
Martínez‐Coria, H., Green, K. N., Billings, L. M., Kitazawa, M., Albrecht, M., Rammes, G., Parsons, C. G., Gupta, S., Banerjee, P., & LaFerla, F. M. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090452 · Cited by 224
The Use of Antiepileptic Drugs—Principles and Practice
Sander, J. W. A. S. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.455005.x · Cited by 217
Schneider, L. S. S., Tariot, P. N., Lyketsos, C. G., Dagerman, K., Davis, K. L., Thomas, S., Hsiao, J., Jeste, D. V., Katz, I. R., Olin, J. T., et al. (2001) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200111000-00004 · Cited by 208
Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Cummings, J. L. (2003) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200303000-00004 · Cited by 203
Alpha-lipoic acid as a new treatment option for Azheimer type dementia
Hager, K., Marahrens, A., Kenklies, M., Riederer, P., & Münch, G. (2001) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(01)00104-2 · Cited by 188
Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide
Oyama, Y., Chikahisa, L., Ueha, T., Kanemaru, K., & Noda, K. (1996) · Brain Research · doi:10.1016/0006-8993(95)01440-3 · Cited by 188
DONGEN, M. C. J. M. V., van Rossum, E., Kessels, A. G. H., Sielhorst, H., & Knipschild, P. G. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb02589.x · Cited by 186
A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Reisberg, ., Doody, R. S., Stöffler, A., Schmitt, F. A., Ferris, S. H., & Möbius, H. J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.49 · Cited by 183
Rountree, S. D., Chan, W., Pavlik, V. N., Darby, E. J., Siddiqui, S., & Doody, R. S. (2009) · Alzheimers Res Ther · doi:10.1186/alzrt7 · Cited by 181
Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes
Natali, A., Baldeweg, S. E., Toschi, E., Capaldo, B., Barbaro, D., Gastaldelli, A., Yudkin, J. S., & Ferrannini, E. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1349 · Cited by 180
Ritchie, C. W., Ames, D. J., Clayton, T. C., & Lai, R. (2004) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.12.4.358 · Cited by 179
A fluid connection: Cholesterol and Aβ
Wolozin, B. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101123198 · Cited by 179
3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous Therapy
Winblad, B. G., Wimo, A. B., Engedal, K., Soininen, H. S., Verhey, F. R. J., Waldemar, G., Wetterholm, A.-L., Haglund, A., Zhang, R., & Schindler, R. J. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000091790 · Cited by 176
Landreth, G. E. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00296-2 · Cited by 169
Opie, J., Rosewarne, R., & O'Connor, D. W. (1999) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.1999.00652.x · Cited by 166
Bars, P. L. L., Kieser, M., & Itil, K. Z. (2000) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017242 · Cited by 164
Hoyer, S. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200082 · Cited by 161
Hormone replacement therapy to maintain cognitive function in women with dementia
Hogervorst, E., Yaffe, K. S., Richards, M., & Huppert, F. A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003799.pub2 · Cited by 159
Ginkgo Biloba for cognitive impairment and dementia
Birks, J., & Evans, J. G. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003120 · Cited by 157
Cohort Study of Vitamin C Intake and Cognitive Impairment
Paleologos, M. S., Cumming, R. G., & Lazarus, R. M. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009559 · Cited by 137
Bakchine, S., & Loft, H. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11409 · Cited by 135
Pancreatic beta-cell loss and preservation in type 2 diabetes
Buchanan, T. A. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80241-2 · Cited by 132
Improved Cognition in Alzheimer’s Disease With Short-Term D-Cycloserine Treatment
Tsai, G. E., Falk, W. E., Gunther, J. M., & Coyle, J. T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.3.467 · Cited by 129
Kontush, A., Mann, U. M., Arlt, S., Ujeyl, A., Lührs, C., Müller‐Thomsen, T., & Beisiegel†, U. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00595-0 · Cited by 129
Fassbender, K. C., Stroick, M., Bertsch, T., Ragoschke, A., Kuehl, S., Walter, S., Walter, J., Brechtel-Curth, K., Muehlhauser, F., von Bergmann, K., et al. (2002) · Neurology · doi:10.1212/wnl.59.8.1257 · Cited by 119
Impact of Estrogen Therapy on Alzheimer??s Disease
Brinton, R. D. (2004) · CNS Drugs · doi:10.2165/00023210-200418070-00001 · Cited by 109
Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761)
Hoyer, S., Lannert, H., Nöldner, M., & Chatterjee, S. S. (1999) · Journal of Neural Transmission · doi:10.1007/s007020050232 · Cited by 102
Kanowski, S., Herrmann, W. M., Stephan, K., Wierich, W., & Hörr, R. (1997) · Phytomedicine · doi:10.1016/s0944-7113(97)80021-9 · Cited by 99
Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid
Lovell, M. A., Xie, C., Xiong, S., & Markesbery, W. R. (2003) · Journal of Alzheimer s Disease · doi:10.3233/jad-2003-5306 · Cited by 92
Klein, J., Chatterjee, S. S., & Löffelholz, K. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00239-4 · Cited by 91
Combination Therapy of Donepezil and Vitamin E in Alzheimer Disease
Klatte, E. T., Scharre, D. W., Nagaraja, H. N., Davis, R. A., & Beversdorf, D. Q. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200304000-00010 · Cited by 83
Folwell, J., Cowan, C. M., Ubhi, K. K., Shiabh, H., Newman, T. A., Shepherd, D., & Mudher, A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.014 · Cited by 83
No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use
Wenk, G. L., Quack, G., Moebius, H. J., & Danysz, W. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00411-2 · Cited by 81
Prehn, J. H. M., & Krieglstein, J. (1993) · Journal of Neuroscience Research · doi:10.1002/jnr.490340205 · Cited by 80
Antipsychotic polypharmacy: evidence based or eminence based?
Stahl, S. M. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.2e011.x · Cited by 78
Tan, M. H., Johns, D., Strand, J., Halse, J., Madsbad, S., Eriksson, J. W., Clausen, J., Konkoy, C. S., Herz, M., & for the GLAC Study Group (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01258.x · Cited by 73
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
Hartmann, S., & Möbius, H. J. (2003) · PubMed · doi:10.1097/01.yic.0000054279.38655.74 · Cited by 72
D-cycloserine for Alzheimer's disease
Jones, R. W., Laake, K., & Øksengård, A. R. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003153 · Cited by 72
van Dyck, C. H., Schmitt, F. A., & Olin, J. T. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000203151.17311.38 · Cited by 62
Russ, C., Lovestone, S., & Powell, J. F. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000852 · Cited by 60
Farlow, M. R., Alva, G., Meng, X., & Olin, J. T. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903434914 · Cited by 60
Free radicals in Alzheimer’s dementia: currently available therapeutic strategies
Rösler, M., Retz, W., Thome, J., & Riederer, P. F. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-7508-8_21 · Cited by 60
Blesa, R., Davidson, M., Kurz, A., Reichman, W. E., van Baelen, B., & Schwalen, S. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000067974 · Cited by 56
Indomethacin for Alzheimer's disease
Tabet, N., & Feldman, H. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003673 · Cited by 50
Schneider, L. S. S., Olin, J. T., & Pawluczyk, S. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.2.321 · Cited by 47
Weiser, M., Rotmensch, H. H., Korczyn, A. D., Hartman, R. D., Cicin-Sain, A., & Anand, R. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.599 · Cited by 46
Use of Estrogens for the Prevention and Treatment of Alzheimer’s Disease
Monk, D., & Brodaty, H. (2000) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017206 · Cited by 45
Milacemide: A Placebo‐Controlled Study in Senile Dementia of the Alzheimer Type
Dysken, M. W., Mendels, J., LeWitt, P. A., Reisberg, ., Pomara, N., Wood, J. B., Skare, S. S., Fakouhi, J. D., & Herting, R. L. (1992) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1992.tb02019.x · Cited by 43
Hormone replacement therapy to maintain cognitive function in women with dementia
Hogervorst, E., Yaffe, K. S., Richards, M., & Huppert, F. A. (2002) · doi:10.1002/14651858.cd003799 · Cited by 43
Olin, J. T., Bhatnagar, V., Reyes, P. F., Koumaras, B., Meng, X., & Brannan, S. K. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2355 · Cited by 42
Combination Therapies and the Theoretical Limits of Evidence-Based Medicine
Saver, J. L., & Kalafut, M. A. (2001) · Neuroepidemiology · doi:10.1159/000054762 · Cited by 41
Carlsson, C. M., Papcke-Benson, K., Carnes, M. L., McBride, P. E., & Stein, J. H. (2002) · Drugs & Aging · doi:10.2165/00002512-200219100-00008 · Cited by 40
Combined Tacrine and Estrogen Replacement Therapy in Patients with Alzheimer's Diseasea,b
Schneider, L. S., & Farlow, M. R. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48482.x · Cited by 39
Pharmacologic therapy for behavioral symptoms of alzheimer's disease
Tariot, P. N., Ryan, J. M., Porsteinsson, A. P., Loy, R., & Schneider, L. S. S. (2001) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(05)70073-2 · Cited by 38
No additional benefit of HRT on response to rivastigmine in menopausal women with AD
Rigaud, A., André, G., Vellas, B. J., Touchon, J., & Péré, J.-J. (2003) · Neurology · doi:10.1212/wnl.60.1.148-a · Cited by 38
Alzheimer's disease: An inflammatory disease?
Fassbender, K. C. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00147-0 · Cited by 35
The use of antidepressants in novel combination therapies.
Shelton, R. C. (2003) · PubMed · Cited by 33
Yao, C., Raoufinia, A., Gold, M., Nye, J. S., Ramael, S., Padmanabhan, M., Walschap, Y., Verhaeghe, T., & Zhao, Q. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005274551 · Cited by 32
Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease
Mohs, R. C., Kawas, C. H., & Carrillo, M. C. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.04.003 · Cited by 32
Parkinson’s disease: Medical treatment of moderate to advanced disease
Suchowersky, O. (2002) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-002-0006-5 · Cited by 32
Bergman, J., Brettholz, I., Shneidman, M., et al. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200303000-00008 · Cited by 32
Glitazones and the management of insulin resistance: what they do and how might they be used
EINHORN, D. F., Aroda, V. R., & Henry, R. R. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.04.003 · Cited by 26
Huang, F., Lasseter, K. C., Janssens, L., Verhaeghe, T., Lau, H., & Zhao, Q. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/0091270002042012005 · Cited by 26
Alpha lipoic acid for dementia
Klugman, A., Sauer, J., Tabet, N., & Howard, R. J. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004244.pub2 · Cited by 22
Extrapyramidal side‐effect due to drug combination of risperidone and donepezil
Liu, H., Lin, S., & SUNG, S. (2002) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2002.01040.x · Cited by 22
Grossberg, G. T., Pn, T., Farlow, M. R., Gergel, I. P., Graham, S. M., & Jin, J. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92212-7 · Cited by 19
Combination of Donepezil and Gabapentin for Behavioral Disorders in Alzheimer's Disease
Dallocchio, C., Buffa, C., & Mazzarello, P. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0114f · Cited by 18
Combination Therapy for Early Alzheimer's Disease: What Are We Waiting for?
Doraiswamy, P. M., & Steffens, D. C. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb04556.x · Cited by 16
Drug Abuse? Use and Misuse of Psychotropic Drugs in Alzheimer's Care
Taft, L. B., & Barkin, R. L. (1990) · Journal of Gerontological Nursing · doi:10.3928/0098-9134-19900801-04 · Cited by 14
Current Therapeutic Strategies for Type 2 Diabetes Mellitus
Loh, K., & Leow, M. K. (2002) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v31n6p722 · Cited by 10
Rapp, M. S., & Kaplan, A. S. (1981) · The Canadian Journal of Psychiatry · doi:10.1177/070674378102600811 · Cited by 8
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Fuchsberger, T., Padberg, F., Faltraco, F., et al. (2002) · PubMed · Cited by 5
A Case Series of d -Cycloserine Added to Donepezil in the Treatment of Alzheimer's Disease
Falk, W. E., Daly, E. J., Tsai, G. E., et al. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.4.466 · Cited by 4
Terapia combinada en la esclerosis múltiple
Merino, J. A. G., Quítez, M. R. B., Benítez, P. O., et al. (2003) · Revista de Neurología · doi:10.33588/rn.3606.2002349 · Cited by 3
Cann, S. A. H., Netten, J. P. V., & Netten, C. V. (2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200003)47:3
Winblad (1999) · doi:10.1002/(sici)1099-1166(199902)14:2
Research works printed but not linked: 5
- Grimaldi, 2000, Ann Neurol, 47, 361, 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N · DOI
- Tabet, 2002, Cochrane Database Syst Rev, &NA;, CD003673
- Hogervorst, 2002, Cochrane Database Syst Rev, &NA;, CD003799
- Fuchsberger, 2002, MMW Fortschr Med, 144, 36
- Loh, 2002, Ann Acad Med Singapore, 31, 722
Cited by
Sorted by citations
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Chemical Constituents and Pharmacological Activities of Garlic (Allium sativum L.): A Review
El-Saber Batiha, G., Magdy Beshbishy, A., G. Wasef, L., Elewa, Y. H. A., A. Al-Sagan, A., Abd El-Hack, M. E., Taha, A. E., M. Abd-Elhakim, Y., & Prasad Devkota, H. (2020) · Nutrients · doi:10.3390/nu12030872 · Cited by 931
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623
Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588
Metadata
- Authors
- Schmitt, B., Bernhardt, T., Moeller, H.-J., Heuser, I., & Fr??lich, L.
- Affiliations
- Heidelberg University (DE)
- Ludwig-Maximilians-Universität München (DE)
- Humboldt-Universität zu Berlin (DE)
- ORCID
- Heuser, Isabella
- Venue
- CNS Drugs
- Published
- 2004
- Volume
- 18
- Issue
- 13
- Pages
- 827-844
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W2135793938
- Cited by
- 182
- References
- 130
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 11 · 2022: 5 · 2021: 9 · 2020: 10 · 2019: 18 · 2018: 15 · 2017: 9 · 2016: 9 · 2015: 11 · 2014: 15 · 2013: 5 · 2012: 12
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, combination therapy, acetylcholinesterase inhibitors, memantine, NMDA receptor antagonists, antioxidants, Ginkgo biloba, anti-inflammatory agents, neurotrophic factors, hormone replacement therapy, insulin signaling, cholesterol-lowering therapy, disease modification, cognitive enhancement, behavioural symptoms, dementia treatment
- MeSH terms
- Alzheimer Disease, Animals, Anti-Inflammatory Agents, Antioxidants, Cholinesterase Inhibitors, Cognition, Combined Modality Therapy, Drug Therapy, Combination, Female, Humans, Male, Estrogen Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
